The estimated Net Worth of Susan Dexter is at least 27.4 千$ dollars as of 14 June 2023. Ms Dexter owns over 10,000 units of Sonnet BioTherapeutics Inc stock worth over 27,449$ and over the last 4 years she sold SONN stock worth over 0$.
Sign up
Ms Dexter SONN stock SEC Form 4 insiders trading
Ms has made over 1 trades of the Sonnet BioTherapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently she bought 10,000 units of SONN stock worth 7,000$ on 14 June 2023.
The largest trade she's ever made was buying 10,000 units of Sonnet BioTherapeutics Inc stock on 14 June 2023 worth over 7,000$. On average, Ms trades about 1,667 units every 0 days since 2020. As of 14 June 2023 she still owns at least 33,667 units of Sonnet BioTherapeutics Inc stock.
You can see the complete history of Ms Dexter stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Susan Dexter biography
Susan Dexter is the Chief Technical Officer at Sonnet BioTherapeutics Inc.
How old is Ms Dexter?
Ms Dexter is 66, she's been the Chief Technical Officer of Sonnet BioTherapeutics Inc since . There are 1 older and 5 younger executives at Sonnet BioTherapeutics Inc. The oldest executive at Sonnet BioTherapeutics Holdings Inc is Dr. John K. Cini Ph.D., 68, who is the Chief Scientific Officer & Co-Founder.
What's Ms Dexter's mailing address?
Susan's mailing address filed with the SEC is 100 OVERLOOK CENTER, SUITE 102, , PRINCETON,, NJ, 08540.
Insiders trading at Sonnet BioTherapeutics Inc
Over the last 8 years, insiders at Sonnet BioTherapeutics Inc have traded over 53,380$ worth of Sonnet BioTherapeutics Inc stock and bought 641,484 units worth 290,512$ . The most active insiders traders include Pankaj Mohan、Donald J. Griffith、Michael D Pruitt. On average, Sonnet BioTherapeutics Inc executives and independent directors trade stock every 86 days with the average trade being worth of 21,474$. The most recent stock trade was executed by Raghu Rao on 27 October 2023, trading 15,625 units of SONN stock currently worth 12,739$.
What does Sonnet BioTherapeutics Inc do?
sonnet biotherapeutics is an early stage company developing a pipeline of bifunctional therapies that attack immune-modulating targets to control cancer cells. sonnet biotherapeutics is utilizing a platform approach to develop a library of cancer-fighting immunotherapies. sonnet is based in cranbury, new jersey. sonnet mission: sonnet biotherapeutics is a platform enabled proof-of-concept engine created to generate immuno-oncology candidates and develop them into phase ii assets. we are leveraging a unique ip driven platform: ● single chain platform with pk enhancement ● selectively targeting tumors and their micro-environment ● validated targets only ● dual targeting can create synergies
What does Sonnet BioTherapeutics Inc's logo look like?
Complete history of Ms Dexter stock trades at Sonnet BioTherapeutics Inc
Sonnet BioTherapeutics Inc executives and stock owners
Sonnet BioTherapeutics Inc executives and other stock owners filed with the SEC include:
-
Dr. Pankaj Mohan Ph.D.,
Founder, Chairman. CEO & Pres -
Dr. Pankaj Mohan,
Founder, Chairman. CEO & Pres -
Jay Cross,
Chief Financial Officer -
Dr. John K. Cini Ph.D.,
Chief Scientific Officer & Co-Founder -
Dr. Richard T. Kenney FACP, M.D.,
Chief Medical Officer -
Manuel Dafonseca,
Head of Clinical Operations -
Dr. Richard T. Kenney,
Chief Medical Officer -
Susan Dexter,
Chief Technical Officer -
Frederick L Glick,
President -
Albert D. Dyrness,
Director -
Lori Mc Neill,
Director -
Gregory Evan Kraut,
Director -
Larry Spitcaufsky,
-
Richard Adams,
-
Neil G Kiefer,
Director -
Russell Jacob Page,
Director -
Keith J Johnson,
Director -
Troy Matson Shadoin,
Chief Accounting Officer -
Patrick Clay Harkleroad,
Chief Financial Officer -
Michael D Pruitt,
CEO, Chairman -
J Eric Wagoner,
Director -
John K. Cini,
Chief Scientific Officer -
Donald J. Griffith,
Director -
Susan Dexter,
Chief Technical Officer -
John Harry Iii Cross,
Chief Financial Officer -
Nailesh Bhatt,
Director -
Pankaj Mohan,
Chairman, President and CEO -
Terence Anthony Rugg,
Chief Medical Officer -
Raghu Rao,
Director -
Richard T Kenney,
Chief Medical Officer